New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 3, 2014
18:56 EDTGSK, KKR, SNYPE firms mull combining older GSK, Sanofi drug brands, FT says
Private equity firms including KKR (KKR) and Warburg Pincus are considering purchasing the older drug portfolios of GlaxoSmithKline (GSK) and Sanofi (SNY) and combining them, says the Financial Times. Reference Link
News For GSK;SNY;KKR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 18, 2015
09:32 EDTSNYMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
08:25 EDTKKRSamson near deal for covenant breach waiver, NY Post says
Subscribe for More Information
08:10 EDTKKRAres Management names Michael McFerran as CFO
Ares Management, L.P. (ARES) announced that it has appointed Michael R. McFerran as Executive VP, CFO and Treasurer, effective March 23. McFerran will assume firm-wide CFO and Treasurer responsibilities. McFerran was previously a Managing Director at Kohlberg Kravis Roberts & Co. L.P. (KKR) where he served as the CFO of KKRís credit business and was the COO and CFO of KKR Financial Holdings LLC (KFN). Daniel F. Nguyen, Ares Managementís current CFO and Treasurer, will remain with Ares as CFO of the Ares Private Equity and Tradable Credit Groups and will continue his involvement with firm M&A activities. The CFO roles for each of the other two Ares investment groups, Direct Lending and Real Estate, will continue to be filled by Penni Roll and Tae-Sik Yoon, respectively. In addition, Roll will continue as CFO of Ares Capital Corporation (ARCC) and Yoon will continue as CFO of Ares Commercial Real Estate Corporation (ACRE).
06:42 EDTKKRUxin raises $170M from KKR, Baidu, others, WSJ says
Chinese used car auctioneer Uxin has raised $170M from backers including KKR (KKR) and Baidu (BIDU), reports the Wall Street Journal. Uxin will primarily use the fund to expand its business-to-consumer operations to complete with rivals Bitauto (BITA) and Autohome (ATHM). Reference Link
March 17, 2015
10:00 EDTSNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:02 EDTSNYSanofi says Shantha will provide up to 37M doses of Shan5
Sanofi Pasteur, the vaccines division of Sanofi, announced that its affiliate Shantha Biotechnics of Hyderabad, India has delivered the first 400,000 doses of its pediatric pentavalent vaccine Shan5 to support the immunization of children in the cities of Gwalior and Jabalpur, both in the state of Madhya Pradesh, India. In December 2014, following a two-year international tender, Shantha was awarded to supply global health organizations with a total of 37M doses of Shan5 in 2015 and 2016, in a ten-dose vial presentation. This tender provides the basis upon which purchase orders will be made for specific vaccine deliveries throughout the period, the company said.
07:53 EDTKKRMatson American Eagle Jack Henry named triple play at Oppenheimer
Subscribe for More Information
07:43 EDTSNYSanofi upgraded to Outperform on abating concerns at Leerink
Leerink upgraded Sanofi to Outperform from Market Perform saying key concerns around the lack of a CEO, Toujeo positioning and guidance are either resolved or largely factored into expectations. The firm believes the company's currency risk is hedged over time and that its multibillion dollar PCSK9 and dupilumab therapy assumptions have further upside potential. It raised its price target for shares to EUR 106 from EUR 85.
07:07 EDTGSKVeeva says selected by GlaxoSmithKline for multichannel CRM
Subscribe for More Information
07:06 EDTGSKVeeva selected by GSK as global multichannel CRM partner
Subscribe for More Information
05:40 EDTSNYSanofi upgraded to Outperform from Market Perform at Leerink
March 16, 2015
09:30 EDTKKRConsortium wants to securitize $5.3B of debt from GE Capital, Reuters says
Subscribe for More Information
08:23 EDTSNYPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:32 EDTGSKEmergent BioSolutions signs agreements with GSK, Oxford University, NIAID
Subscribe for More Information
07:25 EDTKKRChinese consortium enters Philips auction, Reuters says
A consortium consisting of Lattice Power, GSR Ventures, and Temasek has placed a last-minute bid in the auction for Philips' (PHG) lighting components business, reports Reuters, citing two sources familiar with the matter. The sources also said the CVC and KKR (KKR) consortium tabled their potentially leading bid. Philips will enter exclusive talks with the winner early next week. Reference Link
07:16 EDTSNYRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTSNYPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:04 EDTSNYSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
12:41 EDTKKRGE sells Australia-New Zealand consumer lending unit to consortium
Subscribe for More Information
March 13, 2015
10:37 EDTSNYSanofi says NHS England de-lists cabazitaxel, aflibercept
Sanofi announcd that NHS England has confirmed that it is de-listing both cabazitaxel and aflibercept from the Cancer Drugs Fund, so that neither of these medicines will be available to new patients in England on the NHS. It added, "However regarding cabazitaxel NHS England have agreed to engage in talks to explore immediate ways of maintaining access to patients until it is reviewed by NICE." Tarja Stenvall, General Manager for Sanofi in the UK, commented, "We are hugely disappointed that cabazitaxel and aflibercept have been cut from the CDF and that new patients in England will no longer have access to these crucial cancer treatments. However NHS England remains in dialogue with Sanofi to explore immediate ways of maintaining access to patients for cabazitaxel until the outcome of any NICE review. Our concern is for patients who should continue to have access to cabazitaxel until a longer term solution is reached and who may feel confused and uncertain until this happens."
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use